Valuation : Resverlogix Corp.

Market Cap 23.54M 16.94M 14.6M 13.69M 12.5M 1.62B 23.62M 162M 63.37M 817M 63.61M 62.23M 2.71B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 109M 78.69M 67.81M 63.58M 58.04M 7.52B 110M 754M 294M 3.8B 295M 289M 12.59B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 day-27.42%
1 week-35.55%
Current month-30.66%
1 month-30.66%
3 months-32.28%
6 months-42.77%
Current year-33.29%
1 week 0.05
Extreme 0.0495
0.07
1 month 0.05
Extreme 0.0495
0.08
Current year 0.05
Extreme 0.0492
0.1
1 year 0.05
Extreme 0.0492
0.1
3 years 0.02
Extreme 0.023
0.21
5 years 0.02
Extreme 0.023
0.65
10 years 0.02
Extreme 0.023
4.14
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Change 5-day change 1-year change 3-year change Capi.($)
-27.42%-35.55% - - 23.54M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -4.56%-1.93%+59.31%+192.41% 31.33B
Weighted average by Cap. -1.93%-1.50%+57.15%+152.82%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.5M -4.74M -4.44M -4.05M -525M -7.66M -52.67M -20.55M -265M -20.63M -20.18M -879M -7.77M -5.59M -4.82M -4.52M -4.12M -534M -7.79M -53.59M -20.91M -270M -20.99M -20.53M -894M
Net Debt 81.87M 58.93M 50.78M 47.61M 43.46M 5.63B 82.13M 565M 220M 2.84B 221M 216M 9.43B 85.79M 61.75M 53.21M 49.89M 45.54M 5.9B 86.06M 592M 231M 2.98B 232M 227M 9.88B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
28/08/26 US$0.0495 -27.42% 1,300
27/08/26 US$0.0682 -4.88% 11,000